| Melissa K Hammel | |
|
30267 Highland Dr Ardmore TN 38449-3216 | |
| (615) 202-5242 | |
| Not Available |
| Full Name | Melissa K Hammel |
|---|---|
| Speciality | Community/behavioral Health |
| Location | 30267 Highland Dr, Ardmore, Tennessee |
| Authorized Official Name and Position | Melissa K Hammel (OWNER) |
| Authorized Official Contact | 6152025242 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Melissa K Hammel Po Box 39 Ardmore TN 38449-0039 Ph: (615) 202-5242 | Melissa K Hammel 30267 Highland Dr Ardmore TN 38449-3216 Ph: (615) 202-5242 |
| NPI Number | 1356879928 |
|---|---|
| Provider Enumeration Date | 05/26/2017 |
| Last Update Date | 05/26/2017 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356879928 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 251S00000X | Community/behavioral Health | 0000002446 (Tennessee) | Primary |
News Archive
Improving lifestyles now could prevent 12,000 cases (26 per cent) of bowel cancer by the year 2024 - a new report by Cancer Research UK predicts today.
Researchers have discovered how a common mutation in a high-risk leukemia subtype drives the cancer's aggressiveness and have identified drugs that may work with existing precision medicines to improve survival. St. Jude Children's Research Hospital scientists led the study, which was published online today in the journal Cancer Cell.
A new Joslin-led study has identified the insulin receptor as an important protein that promotes islet cell growth in mice whose bodies are unable to use insulin properly, or are insulin resistant, a precursor to type 2 diabetes.
The Senate Appropriations Committee on Thursday plans to mark up a supplemental war appropriations bill that will include language to block for one year seven new Medicaid regulations proposed by the Bush administration, as well as additional funds for FDA, CQ Today reports (Higa, CQ Today, 5/7).
Malvern Panalytical will showcase the new Morphologi G3-ID particle characterization system at Drug Delivery to the Lungs 23, which takes place from 5 – 7 Dec 2012 in Edinburgh, Scotland.
› Verified 2 days ago